BLTE

Belite Bio is a clinical-stage biopharmaceutical company developing small molecule therapies primarily for ophthalmology and rare genetic diseases, with lead programs including BIT-02 for Leber congenital amaurosis and other retinal conditions. The company is conducting clinical trials across multiple jurisdictions including the United States, Australia, China, Europe, and Japan, as evidenced by its engagement with regulatory bodies including the FDA, TGA, NMPA, EMA, and PMDA.

Pipeline

Catalyst Calendar